Movement Disorders

Tardive Dyskinesia drug pipeline

    1 compound from 1 company is in active clinical development for tardive dyskinesia.

    1Compound
    1Company
    0Phase 3+
    1Upcoming readout
    1Trials recruiting
    • Phase 2 1

    Mechanisms: Small molecule (1)

    Pipeline data compiled July 2026 · every fact sourced.

    Upcoming readouts & recent results

    • 1H 2027AnticipatedNBI-1065890Topline dataNCT07365462

      Phase 2 NBI-1065890 vs placebo topline in tardive dyskinesia (primary endpoint: change from baseline in AIMS dyskinesia total score at Week 8) ↗

    See the full catalyst calendar →

    Compounds in development (1)

    CompoundCompanyPhaseStatusMechanism
    NBI-1065890Neurocrine Biosciences, Inc.Phase 2RecruitingVMAT2 Inhibitor

    Trials recruiting now

    1 registered interventional tardive dyskinesia trial — none recruiting at present. Browse all on ClinicalTrials.gov →

    Frequently asked

    How many drugs are in development for tardive dyskinesia?
    1 compound from 1 company is in active clinical development for tardive dyskinesia.
    What are the next tardive dyskinesia trial readouts?
    Upcoming catalysts include NBI-1065890 (1H 2027).